Navigation Links
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
Date:6/2/2008

he factors discussed under the caption "Risk Factors" in Genzyme's Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

Genzyme(R) and Clolar(R) are registered trademarks of Genzyme Corporation. All rights reserved.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Contact:

Maria Cantor Catherine Forte

(617) 768-6690 (617) 768-6881


'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...., Nov. 26 Children who...gnificantly increased risk of developing mental il... a Mayo Clinic study published this month in Pedi...emy of Pediatrics. , , The retrospective st...ith strabismus (misaligned eyes) and compared them...
(Date:11/26/2008)...to 406 Subjects , , FRANKLIN, Mass., Nov. 2...Bulletin Board: PLCSF) announced today that it has...g Administration (FDA) for its U.S. pivotal trial ...uard System(TM) and associated therapy in the pre... , The FDA also approved PLC,s request to exp...
(Date:11/25/2008)..., Nov. 25 Kleinert Kutz...ormed the fifth U.S. hand transplant on Messina, N...le,s Jewish Hospital Hand Care Center on Monday, N... noon and was completed shortly after 9 p.m. in a ....newscom.com/cgi-bin/prnh/20081125/DC48555-a ) , ...
(Date:11/25/2008)...ISCO, Calif., Nov. 25 Proteolix, I... novel therapeutics that target,protein degradati...ay,announced that data from two ongoing Phase 2 c... will be presented at the upcoming 50th Annual Mee... Carfilzomib is the first in a new class,of spec...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 1Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 2Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 1Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 4Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 5Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 6Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 7Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 8Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 9Pre Workout Stretching Wont Prevent Sore Muscles 4020 1Virginia G Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 4018 1Virginia G Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 4018 2Virginia G Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 4018 3Virginia G Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 4018 4
(Date:12/1/2008)...alker Chooses Two Tampa Beneficiaries for Par and ...AMPA, Fla., Dec. 1 The ...rity of Tampa Bay, Inc. and the Judeo Christian He...he 2009 Par and Poker Celebrity Challenge for Char..., , "It is only appropriate that events like...
(Date:12/1/2008)...the sunlight-derived nutrient tied to increased ca...HealthDay News) -- A lack of vitamin D, which is ...elps boost the risk of heart attacks and strokes, ...of studies linking increased cardiovascular risk w...efe, director of preventive cardiology at the Mid ...
(Date:12/1/2008)..., Dec. 1, 2008 The Arthritis Foundation announces...or research in arthritis. The recipients, Dr. Gera...Physicians and Dr. Michel Nussenzweig of Rockefell...ed research advancements in the cure and control o...zed for his research in the development and functi...
(Date:12/1/2008)... Va., Dec. 1 The Food A...d Julia E. Bradsher, Ph.D., as its new CEO, replac..., , Dr. Bradsher brings to FAAN extensive kn...l allergic reaction. For the past six years, as Se...team and strategic planning for all Dey Pharmaceut...
Breaking Medicine News(10 mins):Health News:Celebrity Event Gives Local Non-Profits a Reason to be Thankful 2Health News:Vitamin D Vital for the Heart 2Health News:Vitamin D Vital for the Heart 3Health News:FAAN Names New CEO 2
... more than 57,000 children found that greater the ...ng poor or having a single mother who is a high sc...g sick, immaterial of race or health insurance cov...ved for long that growing up in physically or ment...
... industry a panel comprising European experts reco...a be approved for sales// in the European Union. T...f. The action of the pill Acomplia (rimonabant) i...t obesity. People on the pill eat less because the...
...ce for Wales published, figures for rates of serio...g MRSA. This step is taken to assure// the public ...h officials to protect the public. John Wardell, ...tion after a hip replacement operation at Abergele...
...to be a common problem with the Middle-aged and ol.... But now, Dr. Najah S. Musacchio, a fellow at Chi...p further in finding out if this problem could hav...er and understand, Musacchio and fellow researcher...
Other Medicine News:Health News:A New Study Shows Social Well Being Plays An Important Part In Childs Health 2Health News:A New Study Shows Social Well Being Plays An Important Part In Childs Health 3
Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL.
Kinetic and endpoint methods for the quantitative determination of creatinine in serum.
For the quantitative determination of creatinine in serum. Fixed Time Reaction measured at 540 nm. Linearity: 25 mg/dl. Express Kit with Ready-to-Use Liquid.
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C.
Medicine Products: